Product Reports Resources Pricing Login Book a demo

Optellum

Biotech & Life Sciences · Oxford, United Kingdom · Founded 2016

Developing an artificial intelligence software platform to support clinicians in lung cancer nodule management MoreLess

Optellum is a pioneering health technology startup focused on revolutionizing the early diagnosis and treatment of lung cancer. The company leverages advanced Artificial Intelligence (AI) and Machine Learning (ML) to develop decision support software that aids clinicians in identifying and managing lung cancer at its earliest stages. This innovative approach aims to improve patient outcomes by enabling earlier and more accurate diagnoses, which can significantly reduce waiting times for patients.

Optellum primarily serves healthcare providers, including top hospitals and physicians across Europe and the United States. The company collaborates closely with leading medical experts and institutions, including the Lung Cancer Initiative at Johnson & Johnson, to ensure its solutions are at the forefront of medical innovation.

Operating in the healthcare technology market, Optellum's business model revolves around the development and commercialization of its AI-based software. The company generates revenue by licensing its software to hospitals and medical practices, providing them with a powerful tool to enhance their diagnostic capabilities. This model not only supports the company's growth but also drives significant improvements in patient care.

Optellum's AI software has been validated through multi-center studies in Europe, demonstrating its ability to differentiate between benign and malignant lung nodules. This validation underscores the software's potential to transform lung cancer diagnosis and treatment, making it a valuable asset for healthcare providers aiming to improve patient outcomes.

In summary, Optellum is a cutting-edge health tech company that combines AI and ML to create diagnostic tools for early lung cancer detection. By partnering with top medical institutions and experts, the company aims to enhance the accuracy and efficiency of lung cancer diagnosis, ultimately improving patient care and reducing healthcare costs.

Keywords: AI, lung cancer, early diagnosis, healthcare, machine learning, medical software, patient care, hospitals, clinical experts, innovation.

Company overview

Optellum company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2016
Headquarters
Oxford, United Kingdom
Employees
51
Open positions
1
Dealroom signal
76.4
client focusb2btechnologyArtificial IntelligencetechnologyDeep TechtechnologyMachine LearningtechnologyDeep LearningtechnologyNanotechsub industryBioTechnologysub industryMedical Devicessub industryHealth Platformbusiness modelSaaSindustryHealthsectorRisk ManagementsectorBiotechnologysectorOncology

Valuation & funding

Optellum funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCEquity / VC Nov 2025 $5.7M $23M Undisclosed
LATE VCEquity / VC Jul 2025 $1.8M $37M Undisclosed
LATE VCEquity / VC Mar 2025 $7.4M $70M Undisclosed
SERIES AEquity / VC Sep 2022 $14M $56M Intuitive Ventures · The Oxford Trust · Mercia Asset Management · IQ Capital
SUPPORT PROGRAMOther financing Sep 2020 $0 Tech Nation
EARLY VCEquity / VC Jul 2019 Luminous Ventures
GRANTOther financing Dec 2017 EIT Health
GRANTOther financing Oct 2016 EIT Health
SUPPORT PROGRAMOther financing Jul 2016 EIT Health
SUPPORT PROGRAMOther financing Jan 2016 EIT Health
Showing 10 recorded eventsUnlock the complete deal history →

Financials

Revenue and workforce over time

Available revenue and workforce history. Fields without reported data are omitted.

YearRevenueGrowthEmployees
2026 $4.5M 0% 51
2025 $4.5M 0% 51
2024 $4.5M 0% 48
2023 $4.5M +15.4% 44
2022 $3.9M +30% 45
2021 $3M +25% 30
2020 $2.4M 24
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Optellum website traffic

Latest recorded traffic for Optellum is 8.6K monthly website visits, down 3.4% over the last three months. Optellum's team grew 0% over the past year.

Latest monthly visits8.6K 3-month web change-3.4% 1-year team growth0%
Monthly website visits121 observations · Feb 2016–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Hiring

Open positions at Optellum

Current openings linked to this company in Dealroom.

1 distinct opening shownExplore hiring signals →

Comparisons

Optellum compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Optellum's talent

Book a demo to see the people
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

16 investors on Optellum's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 2 investors entered at this stage
European Innovation Council
EIT Health
Series A 7 investors entered at this stage
Luminous Ventures
Mercia Asset Management
Intuitive Ventures
The Oxford Trust
IQ Capital
Black Opal Ventures
St John’s College
Other known 7 additional known investors
University of Oxford
Tech Nation
BXR Partners LLP
Charles Wiles
Mercia Ventures
Michael Brady
Oliver Keown

Global footprint

Where Optellum has talent and traffic

Workforce by country
5 countries with
team presence
🇬🇧 United Kingdom68.4%
🇺🇸 United States23.7%
🇪🇸 Spain2.6%
🇲🇾 Malaysia2.6%
🇨🇭 Switzerland2.6%
5 countries shown

In the news

Latest news about Optellum

Recent press, funding announcements, and product moves mentioning Optellum — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Optellum

An AI-synthesized read of the highest-engagement posts about Optellum on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Optellum’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.